Ionis Pharmaceuticals Inc. Common Stock (IONS)

FairStock Score: 15/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money consistently, have low debt, and sell below intrinsic value. Ionis fails the first test today. In fiscal 2025, the year ended 2025-12-31, revenue was $943.7 million and net loss was $381.4 million, or diluted EPS of -$2.38. In fiscal 2024, revenue was $705.1 million and net loss $453.9 million. So sales grew, but the company still burned cash: trailing free cash flow was -$567.5 million, a -8.1% FCF yield on a $7.0 billion market cap, per FairStock. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, had revenue $267.9 million and net loss $114.6 million, with diluted EPS -$0.69. That is an improvement from some earlier quarters but not profitability.

In plain English: Ionis makes prescription medicines, including several approved treatments for rare diseases. The business is still losing money, and its latest fiscal year showed a net loss even as revenue rose. At $42.38, the price looks expensive compared with current losses, though the shares are near their 52-week low.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer